Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: A randomized, double-blind, international study

European Journal of Neurology

Volumn 8, Issue 3, 2001, Pages 237-245

  Gruffyd Jones, K ^a   Kies, B ^b   Middleton, A ^c   Mulder, L J M M ^d   Rosjo O ^a   Millson, David S ^e  

^a Box Corsham ^*  (Norway)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Fowley River Practice   (United Kingdom)

^d IKAZIA HOSPITAL   (Netherlands)

^e KEELE UNIVERSITY   (United Kingdom)

Author keywords

5 HT1 receptor agonist; Headache; Migraine; Sumatriptan; Zolmitriptan

Indexed keywords

PLACEBO; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLIDINONES; RECURRENCE; SEROTONIN AGONISTS; SEVERITY OF ILLNESS INDEX; SUMATRIPTAN; TREATMENT OUTCOME; TRYPTAMINES;

EID: 0035009488     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2001.00218.x     Document Type: Article

References (22)

1. Cutler N, Mushet GR, Davis R, Clements MS, Whitcher MHA (1995). Oral sumatriptan for the acute treatment of migraine. Evaluation of three dosage strengths. Neurology 45:S5-S9.
2. Dahlöf CGH, Dimenäs E (1995). Migraine patients experience poorer subjective well being/quality of life even between attacks. Cephalalgia 15:31-36.
3. Dechant KL, Clissold SP (1992). Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine. Drugs 43:776-798.
4. 1B/1D agonist. Cephalalgia 17:41-52.
5. Gallagher RM, Dennish G, Spierings ELH, Chitra R (2000). A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache 40:119-128.
6. Headache Classification Committee of the International Headache Society (1988), Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8:1-96.
7. 1B/1D agonist for migraine. Cephalalgia 17:4-14.
8. Osterhaus JT, Townsend RJ, Gandek B, Ware JE (1994). Measuring the functional status and well-being of patients with migraine headache. Headache 34:337-343.
9. Perry CM, Markham A (1998), Sumatriptan An updated review of its use in migraine. Drugs 55:889-922.
10. Plosker GL, McTavish D (1994). Sumatriptan A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 47:622-651.
11. Rapoport AM, Ramadan NM, Adelman JU et al. on behalf of the 017 Clinical Trial Study Group (1997). Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology 49:1210-1218.
12. Sargent J, Kirchner JR, Davis R, Kirkhart B (1995). Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 45:S10-S14.
13. 1B/1D agonist: an overview of efficacy. Cephalalgia 17:28-40.
14. Seaber EJ, Peck RW, Smith DA et al. (1998). The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br J Clin Pharmacol 46:433-439.
15. Simmons VE, Blakeborough P (1994). The safety profile of sumatriptan. Rev Contemporary Pharmacotherapy 5:319-328.
16. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM on behalf of the 042 Clinical Trial Study Group, (1997). Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 49:1219-1225.
17. Stewart WF, Lipton RB (1994). The economic and social impact of migraine. European Neurol 34:12-17.
18. Stewart WF, Lipton RB, Celentano DD, Reed ML (1992). Prevalence of migraine headache in the United States. JAMA 267:64-69.
19. Stewart WF, Shechter A, Rasmussen BK (1994). Migraine prevalence A review of population based studies. Neurology 44:S17-S23.
20. Tepper SJ, Donnan GA, Dowson AJ et al. (1999), A long-term study to maximise migraine relief with zolmitriptan. Current Opinion Med Res 15:254-271.
21. The International 311C90 Long-Term Study Group (1998). The long-term tolerability and efficacy of oral zolmitriptan ('Zomig', 311C90). An international study. Headache 38:173-183.
22. US prescribing information (1998). Oral Imitrex (sumatriptan), Glaxo Wellcome Inc. Research Triangle Park, North Carolina, USA, February.